ARCA biopharma Inc
Research ARCA biopharma Inc (ORKA) on Bullrun: market cap USD 6.14B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerORKA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 6.14B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 116.25M
- Free cash flow-USD 23.65M
Valuation Snapshot
latest market cap is USD 6.14B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 105.43M | -USD 88.42M | n/a | -3.26 | USD 46.94M | USD 1.93M | USD 471.93M |
| FY2024 | n/a | -USD 83.72M | n/a | n/a | n/a | USD 61.58M | USD 968.00K | USD 382.22M |
| FY2023 | USD 0 | -USD 5.34M | -USD 5.01M | n/a | -0.37 | USD 37.43M | n/a | USD 37.02M |
| FY2022 | USD 0 | -USD 9.93M | -USD 10.91M | n/a | -0.69 | USD 42.45M | n/a | USD 41.67M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 6.14B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.48B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 725.97M | n/a | 99.8% | 19.36 |
Dividend history
| Year | Dividends/share |
|---|---|
| FY2024 | 19.36 USD |
About ARCA biopharma Inc
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ARCA biopharma Inc's market cap?
ARCA biopharma Inc's market capitalization is USD 6.14B.
What does ARCA biopharma Inc do?
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.